Selected research
Industry Research
Myelofibrosis Drug Industry Research Report 2026
Market perspective
The global Myelofibrosis Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Myelofibrosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Myelofibrosis Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Myelofibrosis Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Myelofibrosis Drug include GSK, Suzhou Zelgen Biopharmaceuticals, Novartis, Bristol Myers Squibb, AbbVie, Incyte, Grunenthal, CTI BioPharma and Celgene, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Myelofibrosis Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Myelofibrosis Drug Market by Company
GSK
Suzhou Zelgen Biopharmaceuticals
Novartis
Bristol Myers Squibb
AbbVie
Incyte
Grunenthal
CTI BioPharma
Celgene
Myelofibrosis Drug Segment by Type
JAK 1
JAK 2
Others
Myelofibrosis Drug Segment by Application
Primary Myelofibrosis
Secondary Myelofibrosis
Myelofibrosis Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Myelofibrosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Myelofibrosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Myelofibrosis Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Myelofibrosis Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Myelofibrosis Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Myelofibrosis Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- JAK 1
- JAK 2
- Others
Applications
- Primary Myelofibrosis
- Secondary Myelofibrosis
Companies covered
- GSK
- Suzhou Zelgen Biopharmaceuticals
- Novartis
- Bristol Myers Squibb
- AbbVie
- Incyte
- Grunenthal
- CTI BioPharma
- Celgene
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Myelofibrosis Drug Market Size (2021-2032)
- 2.2.2 Global Myelofibrosis Drug Sales (2021-2032)
- 2.2.3 Global Myelofibrosis Drug Market Average Price (2021-2032)
- 2.3 Myelofibrosis Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 JAK 1
- 2.3.3 JAK 2
- 2.3.4 Others
- 2.4 Myelofibrosis Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Primary Myelofibrosis
- 2.4.3 Secondary Myelofibrosis
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Myelofibrosis Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Myelofibrosis Drug Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Myelofibrosis Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Myelofibrosis Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Myelofibrosis Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Myelofibrosis Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Myelofibrosis Drug, Product Type & Application
- 3.8 Global Manufacturers of Myelofibrosis Drug, Established Date
- 3.9 Global Myelofibrosis Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 GSK
- 4.1.1 GSK Company Information
- 4.1.2 GSK Business Overview
- 4.1.3 GSK Myelofibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 GSK Myelofibrosis Drug Product Portfolio
- 4.1.5 GSK Recent Developments
- 4.2 Suzhou Zelgen Biopharmaceuticals
- 4.2.1 Suzhou Zelgen Biopharmaceuticals Company Information
- 4.2.2 Suzhou Zelgen Biopharmaceuticals Business Overview
- 4.2.3 Suzhou Zelgen Biopharmaceuticals Myelofibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Suzhou Zelgen Biopharmaceuticals Myelofibrosis Drug Product Portfolio
- 4.2.5 Suzhou Zelgen Biopharmaceuticals Recent Developments
- 4.3 Novartis
- 4.3.1 Novartis Company Information
- 4.3.2 Novartis Business Overview
- 4.3.3 Novartis Myelofibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novartis Myelofibrosis Drug Product Portfolio
- 4.3.5 Novartis Recent Developments
- 4.4 Bristol Myers Squibb
- 4.4.1 Bristol Myers Squibb Company Information
- 4.4.2 Bristol Myers Squibb Business Overview
- 4.4.3 Bristol Myers Squibb Myelofibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Bristol Myers Squibb Myelofibrosis Drug Product Portfolio
- 4.4.5 Bristol Myers Squibb Recent Developments
- 4.5 AbbVie
- 4.5.1 AbbVie Company Information
- 4.5.2 AbbVie Business Overview
- 4.5.3 AbbVie Myelofibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 AbbVie Myelofibrosis Drug Product Portfolio
- 4.5.5 AbbVie Recent Developments
- 4.6 Incyte
- 4.6.1 Incyte Company Information
- 4.6.2 Incyte Business Overview
- 4.6.3 Incyte Myelofibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Incyte Myelofibrosis Drug Product Portfolio
- 4.6.5 Incyte Recent Developments
- 4.7 Grunenthal
- 4.7.1 Grunenthal Company Information
- 4.7.2 Grunenthal Business Overview
- 4.7.3 Grunenthal Myelofibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Grunenthal Myelofibrosis Drug Product Portfolio
- 4.7.5 Grunenthal Recent Developments
- 4.8 CTI BioPharma
- 4.8.1 CTI BioPharma Company Information
- 4.8.2 CTI BioPharma Business Overview
- 4.8.3 CTI BioPharma Myelofibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 CTI BioPharma Myelofibrosis Drug Product Portfolio
- 4.8.5 CTI BioPharma Recent Developments
- 4.9 Celgene
- 4.9.1 Celgene Company Information
- 4.9.2 Celgene Business Overview
- 4.9.3 Celgene Myelofibrosis Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Celgene Myelofibrosis Drug Product Portfolio
- 4.9.5 Celgene Recent Developments
5 Global Myelofibrosis Drug Market Scenario by Region
- 5.1 Global Myelofibrosis Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Myelofibrosis Drug Sales by Region: 2021-2032
- 5.2.1 Global Myelofibrosis Drug Sales by Region: 2021-2026
- 5.2.2 Global Myelofibrosis Drug Sales by Region: 2027-2032
- 5.3 Global Myelofibrosis Drug Revenue by Region: 2021-2032
- 5.3.1 Global Myelofibrosis Drug Revenue by Region: 2021-2026
- 5.3.2 Global Myelofibrosis Drug Revenue by Region: 2027-2032
- 5.4 North America Myelofibrosis Drug Market Facts & Figures by Country
- 5.4.1 North America Myelofibrosis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Myelofibrosis Drug Sales by Country (2021-2032)
- 5.4.3 North America Myelofibrosis Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Myelofibrosis Drug Market Facts & Figures by Country
- 5.5.1 Europe Myelofibrosis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Myelofibrosis Drug Sales by Country (2021-2032)
- 5.5.3 Europe Myelofibrosis Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Myelofibrosis Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Myelofibrosis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Myelofibrosis Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Myelofibrosis Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Myelofibrosis Drug Market Facts & Figures by Country
- 5.7.1 South America Myelofibrosis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Myelofibrosis Drug Sales by Country (2021-2032)
- 5.7.3 South America Myelofibrosis Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Myelofibrosis Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Myelofibrosis Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Myelofibrosis Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Myelofibrosis Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Myelofibrosis Drug Sales by Type (2021-2032)
- 6.1.1 Global Myelofibrosis Drug Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Myelofibrosis Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Myelofibrosis Drug Revenue by Type (2021-2032)
- 6.2.1 Global Myelofibrosis Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Myelofibrosis Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Myelofibrosis Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Myelofibrosis Drug Sales by Application (2021-2032)
- 7.1.1 Global Myelofibrosis Drug Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Myelofibrosis Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Myelofibrosis Drug Revenue by Application (2021-2032)
- 7.2.1 Global Myelofibrosis Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Myelofibrosis Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Myelofibrosis Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Myelofibrosis Drug Value Chain Analysis
- 8.1.1 Myelofibrosis Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Myelofibrosis Drug Production Mode & Process
- 8.2 Myelofibrosis Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Myelofibrosis Drug Distributors
- 8.2.3 Myelofibrosis Drug Customers
9 Global Myelofibrosis Drug Analyzing Market Dynamics
- 9.1 Myelofibrosis Drug Industry Trends
- 9.2 Myelofibrosis Drug Industry Drivers
- 9.3 Myelofibrosis Drug Industry Opportunities and Challenges
- 9.4 Myelofibrosis Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst